Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price is charging higher today.

Again.

Shares in the S&P/ASX 300 Index (ASX: XKO) clinical-stage biotechnology company closed yesterday trading for $3.06. In morning trade on Friday, shares are swapping hands for $3.15 apiece, up 2.9%.

This sees the Mesoblast share price up a blistering 1,090% since this time last year.

For some context, the ASX 300 is up 0.8% today and 11.3% over 12 months.

Today's moves come as investors digest Mesoblast's December quarterly report along with a product pipeline update.

Here's what's happening.

Mesoblast share price lifts amid ongoing progress

In the quarter just past, the company – which specialises in allogeneic cellular medicines to treat inflammatory diseases – announced a net operating cash spend of US$10.1 million. While that's still in the red, the net cash spend was down 18% year on year.

Over the three-month period, the Mesoblast share price received a major boost when the company's Ryoncil (remestemcel-L) became the first mesenchymal stromal cell (MSC) therapy approved by the US Food and Drug Administration (FDA) for any indication.

Mesoblast noted that:

FDA approved Ryoncil as the first and only therapy for children aged 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), a life-threatening condition with high mortality rates.

The ASX 300 biotech stock also progressed with its confirmatory Phase 3 trial of rexlemestrocel-L in patients with chronic low back pain, and it reported positive results with its Revascor product for patients with ischemic heart failure and inflammation.

Mesoblast also successfully completed a global private placement, raising US$161 million.

The cash on hand at the end of the quarter was US$38 million, with pro-forma cash after the approximately US$200 million in proceeds raised in January.

What did management say?

Commenting on the results sending the Mesoblast share price higher again today, CEO Silviu Itescu said, "We are committed to making our FDA-approved product Ryoncil available as quickly as possible to the many children with SR-aGVHD in need of life-saving therapy."

Itescu added:

The team has been working relentlessly on finalising product availability, including logistics, regulatory documentation, and contractual arrangements to ensure a successful launch of Ryoncil this quarter.

On the financing front, Itescu said:

The successful financing of US$160 million this month, which provides the company with proforma cash on hand of approximately US$200 million, puts us in a strong position to execute the US commercial launch activities of Ryoncil, to expand the clinical indications of the product, and ensure that commercial manufacturing will meet projected product uptake and demand.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »